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Salvage radiotherapy to the prostate bed is a standard approach for 
men with PSA failure after radical prostatectomy.  It achieves 
biochemical control in around half of cases, and is thought to 
improve overall survival [1]. The addition of hormone therapy to 
radiation enhances the efficacy of primary treatment [2], but until 
now, it was not clear whether it also improved the outcome of 
salvage radiation. 
 
In this month's issue of European Urology, Spratt et al have reviewed 
the two randomized trials addressing this issue [3].  They rightly 
focus more on the RTOG 9601 trial [4] because the longer follow-up 
provides more data on clinically meaningful long-term outcomes.  
The results clearly prove the principle that the addition of hormone 
therapy can improve clinical outcomes after salvage prostate bed 
radiotherapy.  Among men receiving radiation alone, one half of the 
deaths so far were from prostate cancer (64/131).  Among those 
receiving bicalutamide in addition, one third of the deaths so far 
were from prostate cancer (34/108).  The point estimate for the 
absolute benefit of two years of adjuvant bicalutamide was 5% in 
overall survival, and 8% in cause-specific survival.   Given that 
bicalutamide is both cheap and well tolerated, this is a substantial 
benefit.  Treating just 13 men with bicalutamide to prevent one of 
them dying from prostate cancer is worthwhile.   
 
Spratt et al helpfully address the need to identify which patient 
groups may benefit most from adjuvant bicalutamide.  They conclude 
that “men who benefit most … are those with a … PSA >=0.7ng/ml, 
positive margins and Gleason 8-10”.   This conclusion is open to some 
misinterpretation because “with the exception of PSA level, 
interaction tests did not indicate a significant differential benefit” [4].  
In other words, the data from RTOG 9601 are consistent with the 
same relative survival benefit regardless of margin status or Gleason 
score.  Of course, for a given relative benefit, patients with a worse 
prognosis will gain a greater absolute benefit.   
 
The potential predictive role of post-operative, pre-radiotherapy PSA 
level is less clear because, as Shipley et al indicate [4], there was a 
statistically significant interaction of PSA with the treatment effect.  
However, even this apparent subgroup effect should not be accepted 
uncritically.  It is perhaps surprising, but nonetheless true, that most 
subgroup effects, even those with a significant test for interaction, 
are not reproducible [5]. 
 
When a clinical trial reports a potential subgroup effect there are 
standard criteria to judge the credibility of that claim [6]. In this case, 
there are several factors casting doubt on the reliability of the 
apparent interaction between PSA level and reported benefit from 
adjuvant bicalutamide.  The subgroup analysis, the PSA cut-points 
used, and the direction of the effect, were not pre-specified; the effect 
was not consistent across other outcome measures such as freedom 
from metastases; validation from other studies is lacking; and there 
is no obvious biological rationale. In our view, the observation of an 
interaction between PSA level and treatment effect should be 
regarded as hypothesis generating at this time, rather than practice 
changing.  
 
How should men with PSA failure after radical prostatectomy be 
managed in the light of current evidence? The most important 
predictors of overall survival in RTOG 9601 were age and Gleason 
score.  For older men with a shorter life expectancy, particularly 
those with a lower Gleason score, salvage radiation alone is a 
reasonable option.  For healthier younger men, particularly those 
with a higher Gleason score, there is a strong case for adjuvant 
hormone therapy in addition.  Given the evidence that LHRH agonists 
are more effective than bicalutamide monotherapy in other settings 
[7], we favour the former.  The optimum duration of LHRH agonists 
when used in this setting is unknown: one randomised comparison 
from the RADICALS-HD trial is a comparison of 6 months versus 24 
months LHRH agonists [8]. This includes 880 patients having RT in 
the early salvage setting, and 643 patients having RT in the adjuvant 
setting.  
 
There are several important questions for further research.  
Treatment efficacy might be improved further by the use of pelvic 
nodal irradiation in addition to treatment of the prostate bed, as the 
authors note [3], or by the use of newer Androgen Receptor-targeted 
therapy.  Furthermore, as imaging techniques improve, it is possible 
that salvage treatment could be safely delayed until the site of 
recurrent disease is detectable.  Those men with disseminated 
disease could then avoid the need for local radiotherapy, whereas for 
those with localized or oligometastatic disease, radiotherapy could 
be appropriately tailored to each individual. 
 
 
 References 
 
[1] Tendulkar RD, Agrawal S, Gao T et al. , Contemporary Update of a 
Multi-Institutional Predictive Nomogram 
for Salvage Radiotherapy After Radical Prostatectomy.  J Clin 
Oncol. 2016 Aug 15. [Epub ahead of print] 
 
[2] Kumar S , Shelley M, Harrison C et al. Neo-adjuvant and 
adjuvant hormone therapy for localised and locally 
advanced prostate cancer. Cochrane Database Syst Rev. 2006 Oct 
18;(4) 
 
[3]  Spratt DE, Dess RT, Zumsteg ZS et al.   A Systematic Review and 
Framework for the Use of Hormone Therapy with Salvage Radiation 
Therapy for Recurrent Prostate Cancer. European Urology (in press). 
 
[4] Shipley WU, Seiferheld W, Lukka HR et al. Radiation with or 
without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J 
Med. 2017 Feb 2;376(5):417-428.  
 
[5] Wallach JD, Sullivan PG, Trepanowski JF et al.  Evaluation of 
Evidence of Statistical Support and Corroboration of Subgroup 
Claims in Randomized Clinical Trials. JAMA Intern Med.  2017 Apr 
1;177(4):554-560 
 
[6] Sun X, Briel M, Busse JW et al. Credibility of claims of subgroup 
effects in randomised controlled trials: systematic review. 
BMJ. 2012 Mar 15;344:e1553 
 
[7] Tyrrell CJ, Kaisary AV, Iversen P et al. A randomised comparison 
of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration 
in the treatment of metastatic and locally advanced prostate 
cancer. Eur Urol. 1998; 33(5):447-56. 
 
[8] Parker C, Sydes MR, Catton C et al. Radiotherapy and androgen 
deprivation in combination after local surgery (RADICALS): a new 
Medical Research Council/National Cancer Institute of Canada phase 
III trial of adjuvant treatment after radical prostatectomy. BJU Int. 
2007 Jun;99(6):1376-9. 
 
 
 
 
 
